KARACHI: GlaxoSmithKline (GSK) Consumer Healthcare Pakistan Limited has rejected allegations and said consumer health is its top priority.
In a communication sent to Pakistan Stock Exchange (PSX) on May 20, 2022, the company said about the allegations made by the Young Pharmacists Association against DRAP, GSK and various other organisations etc. While we see no basis for these allegations, we take all concerns seriously and where appropriate, we will take the required actions. Consumer’s safety is and has always been our utmost priority.
Paracetamol is the active ingredient in popular pain relief medicines such as Panadol and is widely available in various strengths and formulations for children and adults.
Numerous studies show that paracetamol is a suitable and effective treatment for the whole family when used as directed. Panadol has been on the market for over 60 years, and it has become a trusted pain relief brand and household name for millions of families around the world, including in Pakistan.
Panadol Extend (665 mg modified-release paracetamol) offers clinically proven treatment option for acute or chronic pain, with less frequent dosing and up to eight hours’ pain relief. It is available in countries globally, including countries in Europe (such as Denmark and Finland) and in New Zealand and Australia.
Our key priority is to serve our consumers and we’re committed to deliver and make our products available to consumers who depend on them. Following an increase in demand for Panadol we have immediately responded with increased production and supply remains strong from our factories.
At GSK Consumer Healthcare, consumer safety is our number one priority, and we strive to ensure safe and appropriate use of our products. Accordingly, as the matter remains sub judice, we would refrain from commenting any further, however we undertake to inform you of any subsequent material developments.